Role of proteoglycans and glycosaminoglycans in the pathogenesis of Alzheimer's disease and related disorders: Amyloidogenesis and therapeutic strategies - A review

Toshio Ariga, Tadashi Miyatake, Robert K Yu

Research output: Contribution to journalReview article

68 Citations (Scopus)

Abstract

The extracellular accumulation of amyloid β proteins (Aβs) in neuritic plaques is one of the hallmarks of Alzheimer's disease (AD). The binding of Aβs to extracellular membranes (ECMs) is a critical step in developing AD. Aβs bind to many biomolecules, including lipids, proteins, and proteoglycans (PGs). PGs play several roles in amyloid formation, including promoting the aggregation of Aβs into insoluble amyloid fibrils, which contributes to the increased neurotoxicity of Aβs. Although Aβs readily self-aggregate to form amyloid fibrils in vitro, their binding to PGs and heparin enhances amyloid aggregation and fibril formation. The sulfate moiety in glycosaminoglycans (GAGs), the carbohydrate portion of PGs, is necessary for the formation of amyloid fibrils; no fibrils are observed in the presence of hyaluronic acid (HA), a non-sulfated GAG. PGs and Aβs are known to colocalize in senile plaques (SPs) and neurofibrillary tangles (NFTs) in the AD brain. The binding site of PGs to Aβs has been identified in the 13-16-amino-acid region (His-His-Gln-Lys) of Aβs and represents a unique target site for inhibition of amyloid fibril formation; His13 in particular is an important residue critical for interaction with GAGs. The sulfate moieties of GAGs play a critical role in the binding to Aβs and enhance Aβ fibril formation. Low-molecular-weight heparins (LMWHs) can reverse the process of amyloidosis to inhibit fibril formation by blocking the formation of β-plated structures, suggesting a possible therapeutic approach using LMWHs to interfere with the interaction between PGs and Aβs and to arrest or prevent amyloidogenesis.

Original languageEnglish (US)
Pages (from-to)2303-2315
Number of pages13
JournalJournal of Neuroscience Research
Volume88
Issue number11
DOIs
StatePublished - Aug 15 2010

Fingerprint

Proteoglycans
Glycosaminoglycans
Amyloid
Alzheimer Disease
Low Molecular Weight Heparin
Amyloid Plaques
Sulfates
Therapeutics
Amyloidogenic Proteins
Neurofibrillary Tangles
Amyloidosis
Hyaluronic Acid
Binding Sites
Carbohydrates
Lipids
Amino Acids
Membranes
Brain
Proteins

ASJC Scopus subject areas

  • Cellular and Molecular Neuroscience
  • Medicine(all)

Cite this

Role of proteoglycans and glycosaminoglycans in the pathogenesis of Alzheimer's disease and related disorders : Amyloidogenesis and therapeutic strategies - A review. / Ariga, Toshio; Miyatake, Tadashi; Yu, Robert K.

In: Journal of Neuroscience Research, Vol. 88, No. 11, 15.08.2010, p. 2303-2315.

Research output: Contribution to journalReview article

@article{c018108067484784a57f88c23fcf8da6,
title = "Role of proteoglycans and glycosaminoglycans in the pathogenesis of Alzheimer's disease and related disorders: Amyloidogenesis and therapeutic strategies - A review",
abstract = "The extracellular accumulation of amyloid β proteins (Aβs) in neuritic plaques is one of the hallmarks of Alzheimer's disease (AD). The binding of Aβs to extracellular membranes (ECMs) is a critical step in developing AD. Aβs bind to many biomolecules, including lipids, proteins, and proteoglycans (PGs). PGs play several roles in amyloid formation, including promoting the aggregation of Aβs into insoluble amyloid fibrils, which contributes to the increased neurotoxicity of Aβs. Although Aβs readily self-aggregate to form amyloid fibrils in vitro, their binding to PGs and heparin enhances amyloid aggregation and fibril formation. The sulfate moiety in glycosaminoglycans (GAGs), the carbohydrate portion of PGs, is necessary for the formation of amyloid fibrils; no fibrils are observed in the presence of hyaluronic acid (HA), a non-sulfated GAG. PGs and Aβs are known to colocalize in senile plaques (SPs) and neurofibrillary tangles (NFTs) in the AD brain. The binding site of PGs to Aβs has been identified in the 13-16-amino-acid region (His-His-Gln-Lys) of Aβs and represents a unique target site for inhibition of amyloid fibril formation; His13 in particular is an important residue critical for interaction with GAGs. The sulfate moieties of GAGs play a critical role in the binding to Aβs and enhance Aβ fibril formation. Low-molecular-weight heparins (LMWHs) can reverse the process of amyloidosis to inhibit fibril formation by blocking the formation of β-plated structures, suggesting a possible therapeutic approach using LMWHs to interfere with the interaction between PGs and Aβs and to arrest or prevent amyloidogenesis.",
author = "Toshio Ariga and Tadashi Miyatake and Yu, {Robert K}",
year = "2010",
month = "8",
day = "15",
doi = "10.1002/jnr.22393",
language = "English (US)",
volume = "88",
pages = "2303--2315",
journal = "Journal of Neuroscience Research",
issn = "0360-4012",
publisher = "Wiley-Liss Inc.",
number = "11",

}

TY - JOUR

T1 - Role of proteoglycans and glycosaminoglycans in the pathogenesis of Alzheimer's disease and related disorders

T2 - Amyloidogenesis and therapeutic strategies - A review

AU - Ariga, Toshio

AU - Miyatake, Tadashi

AU - Yu, Robert K

PY - 2010/8/15

Y1 - 2010/8/15

N2 - The extracellular accumulation of amyloid β proteins (Aβs) in neuritic plaques is one of the hallmarks of Alzheimer's disease (AD). The binding of Aβs to extracellular membranes (ECMs) is a critical step in developing AD. Aβs bind to many biomolecules, including lipids, proteins, and proteoglycans (PGs). PGs play several roles in amyloid formation, including promoting the aggregation of Aβs into insoluble amyloid fibrils, which contributes to the increased neurotoxicity of Aβs. Although Aβs readily self-aggregate to form amyloid fibrils in vitro, their binding to PGs and heparin enhances amyloid aggregation and fibril formation. The sulfate moiety in glycosaminoglycans (GAGs), the carbohydrate portion of PGs, is necessary for the formation of amyloid fibrils; no fibrils are observed in the presence of hyaluronic acid (HA), a non-sulfated GAG. PGs and Aβs are known to colocalize in senile plaques (SPs) and neurofibrillary tangles (NFTs) in the AD brain. The binding site of PGs to Aβs has been identified in the 13-16-amino-acid region (His-His-Gln-Lys) of Aβs and represents a unique target site for inhibition of amyloid fibril formation; His13 in particular is an important residue critical for interaction with GAGs. The sulfate moieties of GAGs play a critical role in the binding to Aβs and enhance Aβ fibril formation. Low-molecular-weight heparins (LMWHs) can reverse the process of amyloidosis to inhibit fibril formation by blocking the formation of β-plated structures, suggesting a possible therapeutic approach using LMWHs to interfere with the interaction between PGs and Aβs and to arrest or prevent amyloidogenesis.

AB - The extracellular accumulation of amyloid β proteins (Aβs) in neuritic plaques is one of the hallmarks of Alzheimer's disease (AD). The binding of Aβs to extracellular membranes (ECMs) is a critical step in developing AD. Aβs bind to many biomolecules, including lipids, proteins, and proteoglycans (PGs). PGs play several roles in amyloid formation, including promoting the aggregation of Aβs into insoluble amyloid fibrils, which contributes to the increased neurotoxicity of Aβs. Although Aβs readily self-aggregate to form amyloid fibrils in vitro, their binding to PGs and heparin enhances amyloid aggregation and fibril formation. The sulfate moiety in glycosaminoglycans (GAGs), the carbohydrate portion of PGs, is necessary for the formation of amyloid fibrils; no fibrils are observed in the presence of hyaluronic acid (HA), a non-sulfated GAG. PGs and Aβs are known to colocalize in senile plaques (SPs) and neurofibrillary tangles (NFTs) in the AD brain. The binding site of PGs to Aβs has been identified in the 13-16-amino-acid region (His-His-Gln-Lys) of Aβs and represents a unique target site for inhibition of amyloid fibril formation; His13 in particular is an important residue critical for interaction with GAGs. The sulfate moieties of GAGs play a critical role in the binding to Aβs and enhance Aβ fibril formation. Low-molecular-weight heparins (LMWHs) can reverse the process of amyloidosis to inhibit fibril formation by blocking the formation of β-plated structures, suggesting a possible therapeutic approach using LMWHs to interfere with the interaction between PGs and Aβs and to arrest or prevent amyloidogenesis.

UR - http://www.scopus.com/inward/record.url?scp=77955364852&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77955364852&partnerID=8YFLogxK

U2 - 10.1002/jnr.22393

DO - 10.1002/jnr.22393

M3 - Review article

C2 - 20623617

AN - SCOPUS:77955364852

VL - 88

SP - 2303

EP - 2315

JO - Journal of Neuroscience Research

JF - Journal of Neuroscience Research

SN - 0360-4012

IS - 11

ER -